ABSTRACT
@#According to international medical organizations, the use of efferent therapy that COVID-19 convalescent plasma has shown some results. </br> Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2. This is being studied for administration to patients with COVID-19. Use of convalescent plasma has been studied in outbreak of other respiratory infections, including the 2003 SARS-CoV-1, the 2009-2010 H1N1 influenza virus, and the 2012 MERS-CoV. </br> Although promising, convalescent plasma has not yet been shown to be safety and efficacy of COVID-19 convalescent plasma in clinical trials. </br> Plasmapheresis and membrane plasmapheresis of efferent therapy has been used in clinical toxicology since 1995, in Mongolia.